October 5 (Reuters) – Here’s what you need to know about the coronavirus right now:
AstraZeneca seeks US authorization for drug to prevent COVID-19
AstraZeneca has applied to U.S. regulators for emergency use authorization for its new treatment to prevent COVID-19 in people who respond poorly to vaccines due to weakened immune systems.
In a statement on Tuesday, the Anglo-Swedish drugmaker said it had included in its filing with the Food and Drug Administration data from an advanced trial that showed the drug to reduce by 77% the risk of developing symptoms of COVID-19. Read more
J&J files a request for a vaccine recall authorization
Johnson & Johnson said on Tuesday it had submitted data to the United States Food and Drug Administration for an emergency authorization to use a booster of its vaccine in people 18 years of age and older.
J&J said its submission includes data from an advanced study that found that a booster given 56 days after the primary dose offered 94% protection against symptomatic COVID-19 in the United States and protection from 100% against serious illness, at least 14 days after the booster shot. Read more
The effectiveness of the Pfizer / BioNTech vaccine in preventing coronavirus infection fell to 47% from 88% six months after the second dose, according to data released Monday that U.S. health agencies considered when they decided on the need for booster vaccines. Read more
Australia buys COVID-19 pill from Merck
Australia will buy 300,000 courses of the experimental antiviral pill from Merck & Co, Prime Minister Scott Morrison said on Tuesday, as Victoria recorded the highest number of daily infections of any state in the country since the start of the pandemic.
Molnupiravir, which would be the first oral antiviral drug for COVID-19 if it gets regulatory approval, could halve the chances of dying or being hospitalized for those most at risk of contracting severe COVID-19 , according to experts. Read more
New Zealand said on Tuesday it would start using vaccination certificates as proof of inoculation during large events and other high-risk settings from next month as the country battles the spread of the disease. Delta variant. Read more
Falling business in Japan baffles experts
The number of COVID-19 cases in Japan has fallen to its lowest in nearly a year, just as other parts of Asia grapple with an increase in infections, leaving health experts perplexed and sparking the worry of a winter rebound.
Daily new cases in Tokyo fell to 87 on Monday, the lowest tally since November 2 last year, and a steep drop to more than 5,000 a day in an August surge that hit the medical infrastructure of the capital.
The pattern is the same across the country. Read more
Business in Russia and Ukraine is on the rise
Russian Finance Minister Anton Siluanov is isolating himself, the head of the upper house of parliament said on Tuesday as cases in the country increased and a record number of deaths per day were recorded. In the past 24 hours, at least 895 people have died from COVID-19 in Russia. Read more
Ukraine’s daily coronavirus-related death toll topped 300 for the first time since mid-May, data from the Ministry of Health showed on Tuesday. Read more
China reports no new local cases for first time in more than 3 weeks
China on Tuesday reported no new local cases of COVID-19 for the first time in more than three weeks after outbreaks in Fujian and Heilongjiang provinces were brought under control.
The first case in Fujian in its recent outbreak was reported on September 10 in the city of Putian. The infections then spread to nearby Xiamen, but were contained in Southeast Province.
Compiled by Linda Noakes; Editing by Kirsten Donovan
Our Standards: The Thomson Reuters Trust Principles.